BIS Healthcare Analysts in conversation with Raghavendra Upadhya Assistant Professor Manipal University & Quentin Lubart Project Owner Abbelight.
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick-to-read format.
The document in this series features the global acellular therapy market – strategies and applications, which is currently witnessing great traction from researchers and biopharmaceutical companies. With the advances in the research in regenerative medicine, extracellular vesicles (EVs), or exosomes, which were once thought to be cellular waste produced by by-products of cell homeostasis or injured cells, are now being studied as a key mediator in cell-to-cell communication. Recent research has been centered on developing paracrine-based alternatives to cell-based therapy. Acellular therapy or cell-free therapy offers multiple advantages when compared to cell-based therapies.
BIS Healthcare Analysts in conversation with Raghavendra Upadhya Assistant Professor Manipal University & Quentin Lubart Project Owner Abbelight.
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick-to-read format.
The document in this series features the global acellular therapy market – strategies and applications, which is currently witnessing great traction from researchers and biopharmaceutical companies. With the advances in the research in regenerative medicine, extracellular vesicles (EVs), or exosomes, which were once thought to be cellular waste produced by by-products of cell homeostasis or injured cells, are now being studied as a key mediator in cell-to-cell communication. Recent research has been centered on developing paracrine-based alternatives to cell-based therapy. Acellular therapy or cell-free therapy offers multiple advantages when compared to cell-based therapies.